Quince Therapeutics names Leone Patterson audit, compensation committee chair in board overhaul

• Quince Therapeutics disclosed conditional resignations from directors June Bray, David Lamond, Christopher Senner, effective two business days post-Oct. 6 meeting.
• Departures hinge on shareholder approval of stock issuance tied to Series C Non-Voting Convertible Preferred Stock conversions and related warrants.
• Board slated to add Catherine Bonuccelli, principal at CMB Life Sciences Consulting and former Bellus Health chief medical officer.
• Leone Patterson, former Zymeworks EVP, chief business officer, CFO, set to join as audit and compensation committee chair.
• James Valentine, Hyman, Phelps & McNamara director and former FDA staffer, named governance chair; Drayton Wise, ex-Insmed chief commercial officer, to join.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-411260), on October 02, 2026, and is solely responsible for the information contained therein.